Last reviewed · How we verify
Cultured autologous Mesenchymal Cells
Cultured autologous Mesenchymal Cells are thought to exert their therapeutic effects through immunomodulation and tissue repair.
Cultured autologous Mesenchymal Cells are thought to exert their therapeutic effects through immunomodulation and tissue repair. Used for Treatment of graft-versus-host disease.
At a glance
| Generic name | Cultured autologous Mesenchymal Cells |
|---|---|
| Sponsor | Universidad Autonoma de Madrid |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action is not fully understood, but it is believed that these cells can modulate the immune response and promote tissue repair through the release of various growth factors and cytokines. This can lead to improved outcomes in various therapeutic areas.
Approved indications
- Treatment of graft-versus-host disease
Common side effects
- Infusion-related reactions
- Bacterial infections
- Viral infections
Key clinical trials
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee (NA)
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (PHASE3)
- Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease (PHASE1)
- Angiographic Delivery of AD-MSC for Ulcerative Colitis (PHASE1)
- Investigating the Safety and Regenerative Potential of MSC-Derived Secretome Combined With PRGF in Knee Osteoarthritis (EARLY_PHASE1)
- A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) (PHASE2)
- Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Versus Cultured Allogeneic Adult Umbilical-cord Derived Mesenchymal Stem Cell Intrathecal Injection for SCI (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: